Furthermore, a high SOX9 expression correlates with tumor aggressiveness in liver cancer and enhances sorafenib resistance by modulating the expression of ATP-binding cassette sub-family G member 2 (ABCG2) [11]. This evidence concerns the gene ABCG2 and liver cancer.